Market Research Blog

Corticosteroids Remain the Drug of Choice

Corticosteroids are referred as the first choice of treatment for the inflammation and pain relief. These medications are known to have effects, for example, decreasing tingling, allergic reaction, swelling and redness.

Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which ‘hydrocortisone’ is considered as the first. In addition, increasing innovations have resulted in the advent of topical non-corticosteroids immunomodulators and target medications, for example, immunomodulators such as pimecrolimus and tacrolimus, which in turn, is likely to fuel the growth of the atopic dermatitis treatment market. Moreover, topical corticosteroids are expected to play an important roles in the atopic dermatitis treatment.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3097

North America to Offer High Sales Opportunities

Growth prospects of the atopic dermatitis treatment market are likely to be high in North America over the forecast period of 2022-2029. Factors such as, greater treatment awareness among the patient population across the United States and Canada, early adoption of novel prescriptions, advanced healthcare infrastructure, better and favorable reimbursement policies, and increasing business associations of pharmaceutical organizations with contract research organizations in developing markets will continue to  propel the atopic dermatitis treatment market growth. Despite the fact that the U.S and Canada deal with heavy investment in healthcare infrastructure as well as per capita expenditure, there are increasing number of campaigns organized each year by specific establishments, for example, National Eczema Associations, the PAN Foundation, and pharmaceutical organizations, which are envisaged to work to the advantage of several market vendors.

Hospital Pharmacies – The Key Distribution Channel for Atopic Dermatitis Treatment

Sales of medication for atopic dermatitis treatment through hospital pharmacies will continue to account for relatively high share in the market, as they can stock large range of prescription medicines, including progressively specific and investigational medications. Hospital pharmacies may provide a tremendous amount of medications every day, which is distributed to wards and to intensive care units as per the patient’s prescription schedule.

Topical Drug Administration- A Preferred Mode

Topical mode of administration remains highly preferred among the patient pool of atopic dermatitis. Advent of topical non-corticosteroids immunomodulators is the major factor for the growth in the demand for atopic dermatitis treatment. As topical administration gains prominence, major corticosteroids medications are formulated as topical, in addition to their benefits over oral dosage form.

Atopic Dermatitis Treatment Market: Vendor Insights

The report highlights some of the prominent market players, who have established themselves as leaders in the global atopic dermatitis treatment market. Some of the examples of key players in the global atopic dermatitis treatment market are Sanofi S.A., Galderma S.A., Allergan Plc., Novartis, Bristol-Myers Squibb, Bayer AG, Meda Pharmaceuticals Inc., Astellas Pharma, Inc., Anacor Pharmaceuticals, Inc., Regeneron Pharmaceuticals, and Valeant Pharmaceuticals International, Inc.

Atopic Dermatitis Treatment Market by Category

By Product

• Corticosteroids
• Calcineurin Inhibitors
• Immunosuppressants
• Biologic Therapy
• PDE-4 Inhibitor
• Antibiotics
• Antihistamines
• Emollients

By Indication

• Topical
• Oral
• Injectable

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3097

 By End-User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Mail Order Pharmacies
• Dermatology Clinics

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific excluding Japan
• Japan
• Middle East and Africa (MEA)

The US FDA’s (Food and Drug Administration) proposed UDI (Unique Device Identification) requirements are expected to promote growth in the surgical instrument tracking systems market. According to the UDI rules, labelers (manufacturers, processors, specification formulators, re-packagers, and re-labelers) of surgical instruments are anticipated to administer immediate marking at the individual instrument degree.

The high system costs, long investment cycles, affordable restraints, and technological boundaries are expected to inhibit market growth to some extent. Also, due to the COVID-19 pandemic, there was seen a little drop in growth in the first quarter of 2021.

With elective and non-elective surgeries held up, delayed, or abandoned worldwide, there was a noticeable drop in the application of surgical instrument tracking systems and consumables.

Surgical instrument tracking systems additionally lead to greater monitoring by responsible parties, while limiting medical errors, resulting in increased demand. Other major drivers for market expansion include usability of such solutions in inventory management and during the work cycle, which includes surgeries, storage, sterilization protocols, and post-surgery. As a result of this, total market sales will reach US$ 900 Mn by the ending of 2032.

Emerging economies like India and China, as well as countries in the Middle East, Latin America, and Southeast Asia, are likely to provide major growth possibilities for surgical instrument tracking systems manufacturers.

Rising healthcare costs and improving healthcare infrastructure are likely to provide growth opportunities for market players in all of these economies. The surgical instrument tracking systems market will prosper significantly as a result of this.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14251

Key Takeaways

• In 2022, the North America surgical instruments tracking systems market is expected to account for about 38.5% of the total market.
• The surgical instruments tracking systems market in Asia Pacific is expected to register a CAGR of 19% over the projected period, owing to the region’s unexplored potential opportunities.
• The RFID surgical instruments tracking is expected to gain a lot of traction, with a CAGR of 18.4% by 2032, according to surgical instruments tracking system market forecast.
• Hospital is the dominant sector of surgical instrument tracking systems market, which is estimated to account for more than 33% of revenue by 2026.

Diversification of Portfolio to Be the Key to Market DominanceSome of the major participants in the surgical tool tracking systems market include Fortive Corporation (US), Material Management Microsystems (US), Becton, Dickinson and Company (BD) (US), Haldor Advanced Technologies (US), Getinge AB (Sweden), and STERIS (US), STANLEY Healthcare (US), Surgical Safety Scanner (US) and many others.

To get a stronger foothold in the surgical instruments tracking system market, leading companies are focusing on surgical instrument management, and employing innovative marketing strategies, technological advancements, mergers, and acquisitions.

• Steris, a seller of infection control, surgical equipment, and other hospital supplies, purchased Key Surgical for US$ 850 Mn in October 2020, expanding its geographic reach and adding complementing product lines.
• T-DOC 2000 surgical tool traceability system was created by Getinge AB and Intelligent InSites, Inc. from reprocessing to inventory and logistics to use, the solution supports the sterile supply workflow of instruments, consumables, and implants.
• Flexible 6012 and Flexible 6027 RFID tags, which enable mounting flexibility, are durable, and are IP67-rated, were released in July 2020 by Vizinex RFID(US), making them perfect for tracking a variety of assets in indoor situations.
• In May 2020, STANLEY Healthcare and CISCO linked up. STANLEY’s AeroScout Real-time Location System (RTLS) platform has been completely integrated and certified with CISCO DNA Spaces, the next-generation indoor position services platform, to give healthcare organizations enterprise-wide transparency into the location and condition of equipment and individuals.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14251

Key Segments By Component:

• Software
• Hardware
• Services

By Technology :

• Barcode
• Radio Frequency Identification (RFID)

By End User:

• Hospital
• Public Hospital
• Private Hospital
• Other End Users

By Region:

• North America
• Latin America
• Europe
• Asia-Pacific excluding Japan
• Middle East & Africa

The global drug research services industry is booming as a result of increased funding for research and innovation in a multitude of segments. The drug discovery process is a significant part of the pharmaceutical sector.

Pharmaceutical and biopharmaceutical businesses are opting for seamlessly engaged and multifunctional solution providers for drug discovery research, from the developing phase to the late testing stages. Emerging trends in drug discovery services market portends that pharmaceutical companies opt for outsourcing as a key choice to offset the shortage of in-house manpower required for new product development, as pharmaceutical businesses face great pressure to reduce overhead costs.

Restrictive laws regulating drug research and animal testing are projected to limit drug distribution to some extent. Drug discovery service organizations are facing restrictions due to a limitation of trained employees.

The use of animals in pharmaceutical research is governed by strict laws. Mice, rats, fish, amphibians, and reptiles are the most common animals utilized in scientific studies. Considerations over the ethical use of animal experimentation have prompted countries to enact animal safety and use statutes, which raises a number of impediments to the future of drug discovery services market.

The drug discovery trends indicate that Biologics, such as proteins, peptides, and monoclonal antibodies, account for more than half of the therapeutic possibilities in the initial cycle. In 2022, biologics are estimated to make up for approximately half of the income earned by the top 100 pharmaceutical drugs. As per the global market study on drug discovery services, they provide the drug discovery services market with highest growth potential through the forecast period.

Despite the fact that small-molecule pharmaceutical companies monopolize the global pharmaceutical market, players working with biologics, biosimilars, and large-molecule drugs are tapping into the drug discovery services market opportunities primarily to introduce new biologic-based treatments and rising revenue from current biologics.

All-in-all, the drug discovery services market is expected to reach a valuation of US$ 32 Bn by 2026.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14258

Key Takeaways

• The drug discovery services market is divided into two types–chemistry and biology services. In 2020, the chemistry drug discovery services category held the greatest proportion of the market.
• Small molecules are expected to occupy the largest share of revenue when compared to biologics. Drug discovery statistics specify that small molecules are expected to generate more than US$ 10,800 million in revenue by the end of 2026.
• The oncology category is predicted to have the leading position, owing to the increasing number of cancer patients around the world.
• In comparison to other innovative drug discovery services, Hit-To-Lead identification is expected to acquire the most traction.
• As the most revenue generating phase, several CROs are already delivering Hit-to-lead identification services to pharmaceutical corporations.

“The Asia Pacific drug discovery services market growth is anticipated to be the highest during the projected duration, owing to expansions happening in the pharmaceutical and biopharmaceutical industry. A high proportion of contract research organizations (CROs), government incentives, high research and development in pharmaceutical industry, and the involvement of less restrictive standards for drug discovery programs (particularly in terms of using animals for research) across several APAC countries are some drivers sustaining the healthy growth of the drug discovery services market.”, opines a seasoned FMI analyst.

Competitive LandscapeThe COVID-19 pandemic highlighted the importance of outsourcing drug discovery services for companies and research groups in North America. These companies are now working together with the government to facilitate the drug discovery process.

• Existencia, a business using artificial intelligence in drug discovery, announced a collaboration with Diamond Light Source and Scripps Research on March 31, 2020, to identify COVID-19 antiviral treatments.
• Samsung Biologics, a South Korean pharmaceutical business, has signed a long-term partnership with Eli Lilly and Company to develop bamlanivimab, an investigational COVID-19 virus-neutralizing antibody.
• Genesis Therapeutics and Genentech announced a multi-target drug discovery AI partnership in November 2020. Genesis’ graph machine learning and drug discovery skills will be used in this cooperation to identify novel drug candidates for therapeutic targets in a variety of illness domains.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14258

The emergence of the COVID-19 pandemic has changed the delivery of medical care worldwide. The increased pressure due to the growing rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments for treating patients with COVID-19. It has mild-moderately affected the virology specimen collection market growth.

The Zika virus and Babesia outbreaks, alongside announcements for their inclusion in virology specimen collection tests, indicate the need for innovation in virology specimen collection technologies, consumables, laboratory testing and instruments. Other countries have also undertaken initiatives to check for new and emerging diseases.

The high cost of technologies and collection kits and usage of flow sensitivity screening are the major factors hampering the growth of the virology specimen collection market.

Some emerging markets such as India, the Middle East, and Africa offer promising virology specimen collection opportunities for players in the industry due to their increasing disposable incomes and improving healthcare infrastructure.

The comparatively high cost of laboratory testing has boosted the increasing use of older and less practical tests, for example, first-generation ELISA. The test has been used in various parts of the world despite its limitation.

The high costs of the virology specimen collection products serve as the critical factor curtailing the growth impetus in the market. There is a crucial requirement to reduce the costs of these products to create demand for virology specimen collection. Otherwise, it is estimated to hinder the virology specimen collection growth even in upcoming years.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14266

During the diagnostics investigations, different microbiology specimen collection mediums are recommended to stabilize specimens for the detection of viruses and bacteria. Thus, based on these factors, the virology swab sample market is likely to experience innumerable growth avenues in the forthcoming years. It is expected to have a digital future of public health, and there comes a crucial requirement to align the international strategies for evaluation and regulation.

There is high competition among the virology specimen collection market players. Only major companies can afford high-capital investments and the cost of R&D and manufacturing. That prevents new entrants from entering the virology specimen collection market.

Key Takeaways:

• North America is anticipated to be at the forefront of the virology specimen collection market future trends, which can be attributed to the increasing adoption of NAT and technological advancements such as portable diagnostics.
• The bacterial specimen collection segment is projected to lead the virology collection market trend by product type. The high prevalence of tuberculosis (TB) is one of the significant factors contributing to the share of the segment.
• Diagnostic applications are expected to account for a significant portion of the virology specimen collection market size due to a spike in the number of FDA-approved specimen collection kits, transport of viral specimen, and virology swab sample for clinical applications.
• By end use, the hospitals and clinics segment is anticipated to generate the most revenue, owing to an uptick in patients with respiratory viruses and bacterial infections.
• The Asia Pacific market for bacterial and virology sample collection is expected to grow at a rapid pace because of extensive coronavirus testing in Asian countries.
• By technology, the segment of the nasopharyngeal sample is estimated to hold sway on account of rapid detection of transmissible transfusion infections (TTIs) and the rising prevalence of HPV-related cancers and human papillomavirus (HPV).

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14266

“Virology specimen collection tests emphasize the need for virology specimen collection technology innovation and adoption, consumables, and instruments. This is projected to drive the demand for the virology specimen collection market further.” opines an FMI analyst.

Competitive Landscape:

A few notable virology specimen collection market players include Puritan Medical Products Co. (UK), Trinity Biotech (Ireland), Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Vircell S.L. (Spain), Becton, Quidel Corporation (US), Titan Biotech Ltd. (India), Diasorin SA (Italy), Copan Italia S.P.A (Italy), Hardy Diagnostics (US).

These firms and companies are partnering & collaborating with several domestic and international players as a part of the emerging trends in the viral specimen collection market.

• Henkel AG & Co. KGaA of Germany tied up with Origin of California to leverage the latter’s expertise in performing robust mechanical testing at its California facility. Henkel also contributed expertise and technology to developing 3D printed nasopharyngeal swabs for COVID-19 testing and several other recent developments in the virology specimen collection market.
• Under a USD 6.0 million contract with Inflammatix Inc., the US HHS supported the development of the host-response testing technology. The company is working on three diagnostic tests that will provide quick results on whether the infection is bacterial or viral. This enables clinicians to make better-informed, earlier treatment decisions. Such initiatives are also at the heart of the companies’ strategy to expand earlier diagnosis.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14266

Key Segments By Product Type:

• Blood Collection Kits
• Specimen Collection Tubes
• Viral Transport Media
• Swabs

By Sample:

• Blood Samples
• Nasopharyngeal Samples
• Throat Samples
• Nasal Samples
• Cervical Samples
• Oral Samples
• Other Samples

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa (MEA)

Interoperability and data sharing will become increasingly pivotal and far-reaching for delivering effective healthcare as populations’ worldwide age and people live longer lives, thereby accelerating the healthcare interoperability solutions market growth.

The adoption of cloud technology related to healthcare services is one of the emerging trends in the healthcare interoperability solutions market and a major driving force.

Electronic health record data is rapidly growing, making it difficult to store large amounts of data on local storage devices without risking losing vital information.

The offline mode makes it difficult to share large amounts of data. As a result, healthcare interoperability software solutions are becoming essential and crucial. They enable easy sharing and storage of big data, which spikes the global healthcare interoperability solutions market size.

Furthermore, the government’s implementation of various healthcare reforms has increased the market’s demand for healthcare interoperability solutions.

On the flip side, raising concerns about the safety and security of patient data is putting a brake on the market. Due to the sheer rise in cyber-attacks worldwide, healthcare companies face a significant challenge in protecting patient information.

The pandemic has had a positive impact on the market for healthcare interoperability solutions, and this is expected to shape the healthcare interoperability solutions market future trends.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14264

Pre-COVID, healthcare organizations faced challenges with interoperability and ineffective data management, which were exacerbated during the pandemic, and clinicians missed important COVID-19 information due to interoperability issues in healthcare, which resulted in inpatient treatment delays and clinicians’ inability to document patients’ status adequately.

Due to the rapid changes each day of the pandemic, data exchange was ineffective and challenging to coordinate. With new coronavirus variants causing new COVID-19 outbreaks worldwide, data sharing through interoperability becomes even more critical.

On account of the factors mentioned above, the healthcare interoperability solutions market is likely to garner a revenue of about US$ 5.5 Bn by 2026.

Key Takeaways:

• The services segment is expected to account for the largest share in terms of type in the healthcare interoperability solutions market. The recurring cost of services such as software upgrades/updates and maintenance accounts for a large portion of this segment.
• Based on end use, the healthcare providers segment is anticipated to have the highest CAGR in the healthcare interoperability solutions market during the forecast period. The same can be attributed to the rising need to contain rising healthcare costs, patient volume etc.
• Based on level, structural Interoperability possibly sums up the largest share in the healthcare interoperability solutions market due to the widespread adoption of eHealth system interoperability such as e-prescribing.
• Owing to an uptick in demand for data exchange, the on-premise segment is likely to hold the majority of healthcare interoperability solutions market share based on deployment.
• The diagnosis segment is expected to dominate the healthcare interoperability solutions market, given the growing need for adequate information flow for disease diagnosis, allowing healthcare professionals to assess patients’ conditions fully.

“The market for healthcare interoperability solutions is expected to dominate the North American region. Some of the major factors driving the adoption of healthcare interoperability solutions in this region are the growing demand for high-quality healthcare, the implementation of favourable initiatives, effective EHR implementation by healthcare organizations, and healthcare costs have nearly doubled in the last decade, particularly in the United States.

According to the Organization for Economic Co-operation and Development (OECD), public spending on healthcare and long-term care in OECD countries will rise from 6% of GDP in 2018 to nearly 9% by 2030 and 14% by 2060.” affirms an FMI analyst.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14264

Competitive Landscape in Healthcare Interoperability Solutions Market:The leading companies in the healthcare interoperability solutions market include Koninklijke Philips NV, Interfaceware Inc., Orion Health Group Limited, Infor Inc., Allscripts Healthcare Solutions, Inc., Cerner Corporation, Nextgen Healthcare, Inc., OSP Labs, EPIC Systems Corporation, and Intersystems Corporation.

• Epic Systems is a well-known player in the healthcare interoperability solutions market with registration and scheduling tools, managed care administration and billing applications, and EHR interoperability solutions in healthcare. To promote interoperability, the company launched its novel One Virtual System Worldwide initiative and added new features to its Care Everywhere solution.
• WakeMed Health and Hospitals have invested in Fujifilm’s Synapse VNA and Synapse Accessibility Business viewer to improve health interoperability standards and facilitate real-time coordination, according to FUJIFILM Medical Systems Inc., a significant supplier of clinical imaging and medical informatics software.

Key SegmentsBy Type:

• Software Solutions
• Services

By Level of Interoperability:

• Foundational Interoperability
• Structural Interoperability
• Semantic Interoperability

By End User:

• Healthcare Providers
• Healthcare Payers
• Pharmacies

The sector is booming due to increased demand for antibiotic-resistant bacterial strains, an ageing population, and a high prevalence of hospital-acquired infection. Additionally, a spike in the proportion of product approvals for sepsis diagnosis is expected to promote demand for sepsis diagnostics.

However, factors such as a lack of experienced specialists for diagnosing sepsis, a lack of knowledge, and the adoption of conventional processes during antibiotic production hamper the sales of sepsis diagnostic.

Owing to the rise in newborn umbilical cord infection occurrences and the number of surgical procedures in these countries, developing markets provide a positive outlook for sepsis diagnostics.

HAIs, also known as nosocomial infections, are a leading source of morbidity and mortality in hospitals around the world. Urinary tract infections, pneumonia, and sepsis are the most frequent hospital-acquired infections (HAIs). In addition, in immunocompromised individuals, aged patients, and people with chronic conditions, HAIs can cause sepsis. Because of the significant rise in HAIs around the world, demand for sepsis diagnostic devices is projected to expand in the future years.

Sepsis is a complex condition to detect, and even a one-minute delay in antibiotic delivery increases the chance of death by 7.6% in septic shock patients with hypertension. As a result of the emerging trends in the sepsis diagnostics market, there is a greater need for quick sepsis detection to avoid antibiotic therapy delays in sepsis patients.

Many sepsis diagnostic companies are growing their product offerings in point-of-care technologies, which can quickly identify sepsis, cut down on diagnosis time, and improve life expectancy after sepsis.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14272

Key Takeaways

• Attributed to the presence of a larger consumer population in developing markets such as India and China, the Asia Pacific region of rapid sepsis diagnostics is expected to grow profitably over the forecast period.
• The global sepsis diagnostics market adoption trends indicate North America is likely to generate more than $200 million in revenue by the end of 2026. The sepsis diagnostics companies in the region are growing due to well-established healthcare infrastructure and increased usage of innovative products. Septic poisoning is also one of the leading causes of death in the United States.
• As per the sepsis diagnostics market analysis, microbiology technology is likely to gain traction. Microbiology is expected to generate more than $200 million in income by 2026.
• By product, the sepsis diagnostics market opportunities are divided into blood culture media, assays & reagent kits, devices, and software. The blood culture media segment held the most significant market share during the forecast period. This growth can be ascribed to a rise in blood culture media as a sepsis diagnostics device.

“Sepsis diagnostics device are expensive, limiting the growth of this industry. Additionally, in certain countries, there are no clear guidelines for the treatment of sepsis, and there is a lack of awareness about the repercussions of sepsis if it is not treated effectively.”

Competitive LandscapeOrganizations in the global quality articulation market are consolidating and acquiring systems to gain a competitive advantage and generate significant profits. On the other hand, some players benefit from significant new work systems to gain a competitive advantage in the sepsis diagnostics market statistics.

• Cytovale Inc. and the Biomedical Advanced Research and Development Authority, or BARDA, announced cooperation in April 2020 to increase the use of Cytovale’s Rapid Sepsis Diagnostic System for identifying sepsis in patients with probable respiratory infections, such as COVID-19.
• Immunexpress announced a quick SeptiCyte, a one-hour molecular diagnostic test for sepsis, on Biocartis’ Idylla platform in Europe in October 2020. This is one of the first deeply integrated, immune response-based diagnostics to help clinicians diagnose sepsis and sepsis diagnostics market analysis.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14272

Key SegmentsBy Product:

• Blood Culture Media
• Assays & Reagents
• Instruments, and Software

By Technology:

• Blood Culture
• Immunoassays
• Molecular Diagnostics
• Flow Cytometry
• Microfluidics
• Biomarkers

By Method:

• Automated Diagnostics
• Conventional Diagnostics

By Pathogen:

• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis
• Others

By Test Type:

• Laboratory Tests
• Point-of-Care Tests

By End User:

• Hospitals and Specialty Clinics
• Pathology & Reference Laboratories
• Research Laboratories & Academic Institutes